Found: 6
Select item for more details and to access through your institution.
N-Type Calcium Channel α[sub1B] Subunit (Ca[subv]2.2) Knock-Out Mice Display Hyperactivity and Vigilance State Differences.
- Published in:
- Journal of Neuroscience, 2003, v. 23, n. 17, p. 6793, doi. 10.1523/JNEUROSCI.23-17-06793.2003
- By:
- Publication type:
- Article
P4‐548: CORRELATION OF CEREBROSPINAL FLUID AND PLASMA AMYLOID BETA LEVELS MEASURED BY A NEWLY‐DEVELOPED AUTOMATED PROTEIN ASSAY SYSTEM (HISCL<sup>TM</sup>).
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P1527, doi. 10.1016/j.jalz.2019.08.095
- By:
- Publication type:
- Article
O1‐12‐06: PHASE 1 MULTIPLE ASCENDING DOSE (MAD) STUDY OF PHOSPHODIESTERASE‐9 INHIBITOR E2027: CONFIRMATION OF TARGET ENGAGEMENT AND SELECTION OF PHASE 2 DOSE IN DEMENTIA WITH LEWY BODIES.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P251, doi. 10.1016/j.jalz.2018.06.2401
- By:
- Publication type:
- Article
POPULATION PHARMACOKINETIC-PHARMACODYNAMIC (PK/PD) MODELING OF E2027, A SELECTIVE PHOSPHODIESTERASE-9 (PDE9) INHIBITOR, FOLLOWING SINGLE ASCENDING ORAL DOSES IN HEALTHY VOLUNTEERS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P258, doi. 10.1016/j.jalz.2017.06.123
- By:
- Publication type:
- Article
PHASE 1 INVESTIGATION INTO THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF E2027, A SELECTIVE PHOSPHODIESTERASE-9 (PDE9) INHIBITOR.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P574, doi. 10.1016/j.jalz.2017.07.194
- By:
- Publication type:
- Article
Ataxia and peripheral nerve hypomyelination in ADAM22-deficient mice.
- Published in:
- BMC Neuroscience, 2005, v. 6, p. 33, doi. 10.1186/1471-2202-6-33
- By:
- Publication type:
- Article